ALOSS OF TIME? Abbas Zahedi and Alberto Vallejo 14.10.21 Juf

Abbas Zahedi




Rhizome Analysis: Tumeric





Rhizone Analysis: Ginger







The Lemons the sicilians are Sending us ale not the Same as they sent waiting before / There's a galangal A outside your house / its knocking on your front door.... open up!

Malady, Madaise, Maladowtation

Abbas Zahedi

C3 Neuropharmacology

Introduction: Parkinson's disease (PD) is a debilitating progressive neurodegenerative disorder which affects at least 1% of the global nonulation. Doubting progressive neurodegenerative disorder matching progressive neurodegenerative disorder which affects at least 1% of the global population. Furthermore it has been documented that every general practitioner in the United Kingdom treats multiple actions in the second United Kingdom treats multiple patients with the disease, and there is yet to exist a general consensus on the most its most effective the second sec on the most its most effective therapy¹. Symptoms of PD are typified by the slowness or loss of movement (akinesis) movement (akinesia), muscle stiffness, rigidity, and resting tremors affecting the extremeties. The underlying cause of the discussion of underlying cause of the disease is loss of neural connectivity between the substantia nigra (SN) and caudate-striatum two between the substantia nigra (SN) and caudate-striatum, two brain regions which are indispensable in motor function. These neurones contain dopamine (DA) and it is the dopamine (DA), and it is the resultant decrease of DA due to neural death which leads to the onset of disease². Establishing disease². Establishing a cause for PD is yet to be done, thus the main focus of clinicians treating patients with PD is symptomatic drug therapy. Most treatments revolve around the neurobiology of DA, with levodopa (L-DOPA) being the most common. L-DOPA is a precursor for intracellular synthesis of DA, by the enzyme dopa-decarboxylase. Because this enzyme only exists in dopaminergic neurones, as the progressive nature of the disease persists there will ultimately be no site of action remaining for L-DOPA. This has serious implications in the use of this drug for treating patients with PD. The fluctuations which occur between the positive and negative effects of L-DOPA mark the beginning of the end for the usefulness of this drug. This results in a process clinically reffered to as the 'wearing-off' period, and after this period choice of therapy is very limited indeed³. Thus it is obvious why there is pertinent need for new treatments with higher efficacy and much more prolonged effect. Recently a newly discovered drug termed 'Movin' caused a stir in the research community, due to its positive effects against parkinsonian symptoms, when tested in an animal model of the disease⁸. This was the MPTP-treated primate model, which is known to be the most accurate reproduction of the human disease in animals. This model involves immunoreactive degeneration of neurones relevent to PD in the brain and has contributed significantly to developments in the fight against PD⁴. The data shows that a modest dose of the drug (when compared to current drugs) is of use in reducing PD related symptoms such as akinesia and rigidity, though the mechanisms involved in doing so remain to be elucidated. Therefore I wish in this proposal to study the effects of Movin as a potential treatment for

PD and determine a putative understanding of its mechanism for action. I will achieve this by using rodent models of the disease (presented below); which like the MPTP-primate model, have proven to be of great value, and were amongst the first animal models to accurately recreate parkinsonian Preliminary Results: THE LOSS OF MOVEMENT =

Experiment 1:

Experiment 1: The reservine rodent model of Parkinson's disease is a well established test for the effect of drugs The reservine rodent model of the vesicular monoamine transporter 2 (VMAT-2) and prevents storage of against PD. Reservine DA to build up in the cytosol of the neurone. Independent against PD. Reserpine bilds to build up in the cytosol of the neurone. Independent of exocytosis DA in vesicles, this causes DA to build up in the cytosol of the neurone. Independent of exocytosis DA DA in vesicles, this causes by the and causes a brief augmentation of dopaminergic function, after which is released into the synaptic cleft and causes a brief augmentation. The effects of reserving also is released into the synaptic clert and the in DA transmission. The effects of reservine closely mimic the depleted neurones no longer partake in DA transmission. The effects of reservine closely mimic the the depleted neurones no longer particle of L-DOPA reverses the effects of reserpine closely mimi decline in motility associated with PD. Addition of L-DOPA reverses the effects of reserpine as is shown in the following experiment:

LOSS OF TIME


The activity of mice running on a rotating treadmill was recorded after administration of the The activity of mice running on a rotating treatment and and administration of the aforementioned drugs. Mice were tested against a negative control mouse which did not receive any aforementioned drugs. Mice was determined by the number of rotations resulted from the analysis of mass resulted from the second drugs and the second drugs are second drugs. aforementioned drugs. Mice were tested against a treat which did not receive any aforementioned drugs. Mice were tested against a treat which did not receive any drug. The activity of each mouse was determined by the number of rotations resulted from its walking drug. The activity of each mouse was determined was saved by a community which passed each mouse was determined by the number of rotations was saved by a community of the treatment of t drug. The activity of each mouse was determined of the set of magnets which passed each other of running in the treadmill. We quantified these rotations was saved by a computer linked to the drug. The activity of the quantified these rotations was saved by a computer linked to the apparatus. The drug dependent models we used in this study are listed below:


-1-


Malady, Malaise, Maladaptation

Alberto Vallejo
















Abbas Zahedi's interdisciplinary practice blends contemporary philosophy, poetics, and social dynamics with sound, sculpture, and other performative media. With an emphasis on how personal and collective histories interweave, Zahedi makes connections whenever possible with those around, in proximity to, or involved with the particular situations upon which he focuses.

Alberto Vallejo is an artist and curator based in Madrid where he co-curates the independent art space Yaby since 2017.

jufjuf.org